Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

COLLEGIUM PHARMACEUTICAL, INC Director's Dealing 2021

Jan 21, 2021

32163_dirs_2021-01-21_44f0e9f4-3adc-447b-a09b-b3f4e1684d48.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK: 0001267565
Period of Report: 2021-01-19

Reporting Person: Kuhlmann Shirley R. (EVP and General Counsel)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-01-19 Common Stock A 45360 Acquired 102891 Direct
2021-01-19 Common Stock A 6772 Acquired 109663 Direct
2021-01-20 Common Stock S 6081 $24.45 Disposed 103582 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-01-19 Stock Option (Right to Purchase) $24.06 A 129600 Acquired 2031-01-19 Common Stock (129600) Direct

Footnotes

F1: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2022, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.

F2: On January 19, 2021, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to 6,772 performance share units granted in two prior years.

F3: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.

F4: Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2022, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer.